Nephrol Dial Transplant (2001) 16: 2018-2027
© 2001 European Renal Association-European Dialysis and Transplant Association
The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review
For EUVAS (European vasculitis study group)
1 Department of Nephrology, Medical School Hannover, Germany, 2 Department of Nephrology, Queen Elizabeth Medical Centre, Birmingham, UK and 3 Renal Immunobiology Laboratory, University of Birmingham, Birmingham, UK
Background. The study aimed at studying efficacy and adverse effects of pulse cyclophosphamide (pCyc) treatment and to compare it to continuous cyclophosphamide (cCyc) for induction of remission in ANCA-associated vasculitides from data in the published literature.
Methods. A Medline search identified 14 studies, containing more than five patients. From the 11 non-randomized studies, data on outcome following pCyc treatment were extracted. Results were given as fraction of the number of evaluable patients. A meta-analysis was performed on the three prospective, randomized controlled trials to compare outcomes concerning remission, relapses, infection, leucopenia, death and renal failure in patients treated with pCyc as opposed to cCyc.
Results. The 11 non-randomized studies comprised 202 patients receiving pCyc. Cyc pulses of 375–1000 mg/sqm/pulse were applied at weekly to monthly intervals with different concomitant prednisolone regimens and variable adjunctive therapy. Complete remission was achieved in 112/191, partial remission in 23/191 evaluable patients. Relapses occurred in 68/135 patients, 40/115 patients were non-responders. Leucopenia, infections, haemorrhagic cystitis, and deaths were rare. The meta-analysis, comprising 143 patients, showed that pCyc compared with cCyc treatment was significantly less likely to fail to induce remission (OR 0.29; 95% CI 0.12–0.73) and had a significantly lower risk of infection (OR 0.45; 95% CI 0.23–0.89) and leucopenia (OR 0.36; 95% CI 0.17–0.78). Relapses occurred slightly, although not statistically significantly, more often under pCyc treatment (OR 1.79; 95% CI 0.85–3.75). There were no differences in end-stage renal failure or deaths between the two regimens.
Conclusions. The currently available, rather sparse data show that pCyc is less toxic than cCyc therapy and is an at least equally potent inductor of remission, but possibly at the expense of a higher relapse rate. The existing data do not give sufficient information on outcomes as time to remission and relapse, irreversible damage or quality of life without which a treatment regimen cannot satisfactorily be evaluated today. A large prospective randomized controlled trial is needed to address these issues and their relative importance.
Keywords: continuous cyclophosphamide; meta-analysis; microscopic polyangiitis; pulse cyclophosphamide; Wegener's granulomatosis
Correspondence and offprint requests to: Kirsten de Groot, MD, Department of Nephrology, Medical School Hannover, Carl Neuberg Str. 1, D-30625 Hannover, Germany. Email: kirsten{at}de\|[hyphen]\|grot.de
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. de Groot, L. Harper, D. R.W. Jayne, L. F. Flores Suarez, G. Gregorini, W. L. Gross, R. Luqmani, C. D. Pusey, N. Rasmussen, R. A. Sinico, et al. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody--Associated Vasculitis: A Randomized Trial Ann Intern Med, May 19, 2009; 150(10): 670 - 680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C Mukhtyar, L Guillevin, M C Cid, B Dasgupta, K de Groot, W Gross, T Hauser, B Hellmich, D Jayne, C G M Kallenberg, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis Ann Rheum Dis, March 1, 2009; 68(3): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Specks Pulmonary Vasculitis and Alveolar Hemorrhage Syndromes ACCP Pulmonary Med Brd Rev, January 1, 2009; 25(0): 687 - 704. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Pagnoux, A. Mahr, M. A. Hamidou, J.-J. Boffa, M. Ruivard, J.-P. Ducroix, X. Kyndt, F. Lifermann, T. Papo, M. Lambert, et al. Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis N. Engl. J. Med., December 25, 2008; 359(26): 2790 - 2803. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Hu, C. Liu, H. Xie, H. Chen, Z. Liu, and L. Li Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1307 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Salama, H. T. Cook, C. D. Pusey, and R. J. Pepper A Case of Treated ANCA-Associated Vasculitis with Recurrent Renal Failure Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 637 - 645. [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review JAMA, August 8, 2007; 298(6): 655 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Mukhtyar, D. Boumpas, C. Gordon, W. Gross, D. Jayne, and R. Luqmani Why we need guidelines for clinical trials in vasculitis and systemic lupus erythematosus Ann Rheum Dis, May 1, 2007; 66(5): 569 - 570. [Full Text] [PDF]
|
|
|
|
|
|
B. Hellmich, O. Flossmann, W. L Gross, P. Bacon, J. Willem Cohen-Tervaert, L. Guillevin, D. Jayne, A. Mahr, P. A Merkel, H. Raspe, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Ann Rheum Dis, May 1, 2007; 66(5): 605 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Miyawaki, J. Shiraishi, Y. Tsutsumi, E. Shiraishi, K. Ohtsuki, M. Inoue, T. Tatsumi, A. Azuma, and H. Matsubara Beneficial Effect of Gabexate Mesilate on Microscopic Polyangiitis With Renal Dysfunction and Pulmonary Hemorrhage: A Case Report Angiology, August 1, 2006; 57(4): 522 - 525. [Abstract] [PDF]
|
|
|
|
 |
|
 M. D. Morgan, L. Harper, J. Williams, and C. Savage Anti-Neutrophil Cytoplasm-Associated Glomerulonephritis J. Am. Soc. Nephrol., May 1, 2006; 17(5): 1224 - 1234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Foster, E Rosenthal, S Marques, P Vounotrypidis, S Sangle, and D D'Cruz Primary systemic vasculitis: treatment of difficult cases Lupus, March 1, 2006; 15(3): 143 - 147. [Abstract] [PDF]
|
|
|
|
 |
|
 D. R. Thickett, A. G. Richter, N. Nathani, G. D. Perkins, and L. Harper Pulmonary manifestations of anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis Rheumatology, March 1, 2006; 45(3): 261 - 268. [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Frankel, G. P. Cosgrove, A. Fischer, R. T. Meehan, and K. K. Brown Update in the diagnosis and management of pulmonary vasculitis. Chest, February 1, 2006; 129(2): 452 - 465. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Brown Pulmonary vasculitis. Proceedings of the ATS, January 1, 2006; 3(1): 48 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Hogan, R. J. Falk, H. Chin, J. Cai, C. E. Jennette, J. C. Jennette, and P. H. Nachman Predictors of Relapse and Treatment Resistance in Antineutrophil Cytoplasmic Antibody-Associated Small-Vessel Vasculitis Ann Intern Med, November 1, 2005; 143(9): 621 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Watts, L. Harper, D. Jayne, J. Levy, C. Pusey, C. Savage, D. G. I. Scott, and J. Williams Translational research in autoimmunity: aims of therapy in vasculitis Rheumatology, May 1, 2005; 44(5): 573 - 576. [Full Text] [PDF]
|
|
|
|
 |
|
 S K Frankel, G P Cosgrove, and K K Brown Small vessel vasculitis of the lung Chronic Respiratory Disease, April 1, 2005; 2(2): 75 - 84. [Abstract] [PDF]
|
|
|
|
|
|
A. D. Booth, C. D. Pusey, and D. R. Jayne Renal vasculitis--an update in 2004 Nephrol. Dial. Transplant., August 1, 2004; 19(8): 1964 - 1968. [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shafiei, E. Luther, M. Archie, J. Gulick, and M. R. Fowler Wegener Granulomatosis: Case Report and Brief Literature Review J Am Board Fam Med, November 1, 2003; 16(6): 555 - 559. [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Collins, M. I. Periquet, J. R. Mendell, Z. Sahenk, H. N. Nagaraja, and J. T. Kissel Nonsystemic vasculitic neuropathy: Insights from a clinical cohort Neurology, September 9, 2003; 61(5): 623 - 630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Jayne, N. Rasmussen, K. Andrassy, P. Bacon, J. W. C. Tervaert, J. Dadoniene, A. Ekstrand, G. Gaskin, G. Gregorini, K. de Groot, et al. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies N. Engl. J. Med., July 3, 2003; 349(1): 36 - 44. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Tesar, Z. Rihova, E. Jancova, R. Rysava, and M. Merta Current treatment strategies in ANCA-positive renal vasculitis--lessons from European randomized trials Nephrol. Dial. Transplant., July 1, 2003; 18(90005): v2 - 4. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kamesh, L. Harper, and C. O. S. Savage ANCA-Positive Vasculitis J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1953 - 1960. [Full Text] [PDF]
|
|